Clinical Trials Directory

Trials / Unknown

UnknownNCT04277767

The Role of Ophthalmologic Tests and EEG Imaging in Alzheimer's Disease

The Combination of Ophthalmologic Tests and EEG Imaging as a New Biomarker for Alzheimer's Disease

Status
Unknown
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University · Academic / Other
Sex
All
Age
50 Years – 70 Years
Healthy volunteers
Accepted

Summary

Alzheimer's disease (AD) is a prevalent, long-term progressive degenerative disorder with great social impact. It is currently thought that, in addition to neurodegeneration, vascular changes also play a role in the pathophysiology of the disease. Meantime, EEG resting state has also demonstrated significant change in patients with AD in neuroscience research area. Thus, the combination of these sensitive biomarkers would lead to a potential new biomarker for detection of AD, which has higher specificity and sensitivity.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTobservationalNo intervention

Timeline

Start date
2022-09-01
Primary completion
2023-02-01
Completion
2023-07-01
First posted
2020-02-20
Last updated
2021-04-01

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04277767. Inclusion in this directory is not an endorsement.